*In-license or other partnership with third party.
†Collaboration and license alliance between GSK and iTeos Therapeutics.
BCMA, B-cell maturation antigen; CD, cluster of differentiation; IgG1, immunoglobulin G1; MOA, mechanism of action; MOD, mechanism of disease; NSCLC, non-small cell lung cancer; PARP, poly ADP ribose polymerase; PARPi, poly ADP ribose polymerase inhibitor; PD‑1, programmed cell death protein 1; PVRIG, poliovirus receptor–related immunoglobulin; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T-cell immunoglobulin and mucin domain-3.